AI-extracted from the 10-Q filed 2026-07-31 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Q2 revenue declined 10.5% YoY to $190.7M, driven by reimbursement headwinds across all segments and $11M in prior-period revenue adjustments, while operating losses narrowed to $38.9M.
Biggest Revenue Drivers
Cancer Care Continuum$114.1M-10.6% YoY
15% decrease in revenue per test due to declines in reimbursement, partially offset by 6% volume increase
Mental Health$36.8M-2.6% YoY
4% increase in volume, offset by 6% decrease in revenue per test from unfavorable estimates on aged orders
Biggest Revenue Drivers
Total revenue: $190.7M-10.5% YoY
Cancer Care Continuum$114.1M-10.6% YoY
15% decrease in revenue per test due to declines in reimbursement, partially offset by 6% volume increase
Mental Health$36.8M-2.6% YoY
4% increase in volume, offset by 6% decrease in revenue per test from unfavorable estimates on aged orders
Largest Expense Items
Sales and marketing expense$83.1M+15.6% YoY
$5.0M increase in personnel-related costs and $4.2M increase in marketing and sales expenses
Cost of revenue$63.7M+3.9% YoY
Increased fulfillment costs and personnel-related expenses
Research and development expense$25.0M-2.3% YoY
Relatively consistent with prior year period
Watch Items from the Filing
Revenue concentration in three segments: Cancer Care 60%, Prenatal Health 21%, Mental Health 19%; reimbursement declines persist across all lines, with $11M in Q2 revenue adjustments for prior-period estimates.
Goodwill and intangible asset impairment charges: $4.5M recorded in Q1 2026 for Women's Health reporting unit, reducing goodwill to zero; remaining goodwill of $47.1M ($29.8M Mental Health, $17.3M International) faces ongoing pressure.
Debt covenant compliance: $125M term loan outstanding bears 10.1% interest; minimum revenue covenant of $615M (Dec 2025) increases to $974M by Dec 2029; company was in compliance as of June 30, 2026.
Qui tam litigation unsealed January 2025; court denied motion to dismiss on July 9, 2026, except for one count; no material accrual recorded; litigation remains ongoing with uncertain outcome.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
About MYRIAD GENETICS INC (MYGN): stock profile, AI score and financials
MYRIAD GENETICS INC (MYGN) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores MYGN at 30.8/100 on a composite quality score built from its SEC filings, placing it at rank #2,454 of 2,925 stocks — the bottom half of the AI-ranked universe. Areas of concern include institutional flow (1.8) and balance sheet strength (12.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 26.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q4 2026), MYRIAD GENETICS INC reports quarterly revenue of $190.7M, net income of $-43.2M, an operating margin of -20.4%. Top institutional holders of MYGN by reported 13-F value include BlackRock, MILLENNIUM MANAGEMENT, Vestal Point Capital, based on the most recent SEC filings. MYGN trades on the Nasdaq exchange and files with the SEC under CIK 899923. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MYGN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for MYRIAD GENETICS INC directly from SEC EDGAR.